메뉴 건너뛰기




Volumn 153, Issue 8, 2008, Pages 1650-1658

Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction

Author keywords

Amylase; CCK1 receptor; Cholecystokinin (CCK); Lipase; Pancreatitis

Indexed keywords

3 [5 (3,4 DICHLOROPHENYL) 1 (4 METHOXYPHENYL) 1H PYRAZOL 3 YL] 2,3 TOLYLPROPIONIC ACID; AMYLASE; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEXLOXIGLUMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JNJ 17156516; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

EID: 42149107979     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.44     Document Type: Article
Times cited : (11)

References (22)
  • 1
    • 0032217267 scopus 로고    scopus 로고
    • IkappaB-NF-kappaB structures: At the interface of inflammation control
    • Baeuerle PA (1998). IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 11: 729-731.
    • (1998) Cell , vol.11 , pp. 729-731
    • Baeuerle, P.A.1
  • 2
    • 0033060260 scopus 로고    scopus 로고
    • Potential role of cholecystokinin in the development of acute pancreatitis
    • Beglinger C (1999). Potential role of cholecystokinin in the development of acute pancreatitis. Digestion 60 (Suppl 1): 61-63.
    • (1999) Digestion , vol.60 , Issue.SUPPL. 1 , pp. 61-63
    • Beglinger, C.1
  • 3
    • 27644515221 scopus 로고    scopus 로고
    • Advanced qRT-PCR technology allows detection of the cholecystokinin 1 receptor (CCK1R) expression in human pancreas
    • Galindo J, Jones N, Powell GL, Hollingsworth SJ, Shankley N (2005). Advanced qRT-PCR technology allows detection of the cholecystokinin 1 receptor (CCK1R) expression in human pancreas. Pancreas 31: 325-331.
    • (2005) Pancreas , vol.31 , pp. 325-331
    • Galindo, J.1    Jones, N.2    Powell, G.L.3    Hollingsworth, S.J.4    Shankley, N.5
  • 5
    • 0032805832 scopus 로고    scopus 로고
    • Cholecystokinin induction of mob-1 chemokine expression in pancreatic acinar cells requires NF-kappaB activation
    • Han B, Logsdon CD (1999). Cholecystokinin induction of mob-1 chemokine expression in pancreatic acinar cells requires NF-kappaB activation. Am J Physiol 277: C74-C82.
    • (1999) Am J Physiol , vol.277
    • Han, B.1    Logsdon, C.D.2
  • 6
    • 35548948991 scopus 로고    scopus 로고
    • Design of concise, scalable route to a cholecystokinin 1 (CCK 1) receptor antagonist
    • Liang JT, Mani NS, Jones TK (2007). Design of concise, scalable route to a cholecystokinin 1 (CCK 1) receptor antagonist. J Org Chem 72: 8243-8250.
    • (2007) J Org Chem , vol.72 , pp. 8243-8250
    • Liang, J.T.1    Mani, N.S.2    Jones, T.K.3
  • 7
    • 0024506160 scopus 로고
    • The role of cis-acting promoter elements in tissue-specific albumin gene expression
    • Maire P, Wuarin J, Schibler U (1989). The role of cis-acting promoter elements in tissue-specific albumin gene expression. Science 244: 343-346.
    • (1989) Science , vol.244 , pp. 343-346
    • Maire, P.1    Wuarin, J.2    Schibler, U.3
  • 8
    • 35548998776 scopus 로고    scopus 로고
    • JNJ-17156516 (3-[5-(3,4-dichloro-phenyl)-1-(4-methoxy-phenyl)- 1H-pyrazol-3-yl]-2-m-tolyl-propionate) a novel, potent and selective CCK1 receptor antagonist. In vitro and in vivo pharmacological comparison with dexloxiglumide
    • Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE et al. (2007). JNJ-17156516 (3-[5-(3,4-dichloro-phenyl)-1-(4-methoxy-phenyl)- 1H-pyrazol-3-yl]-2-m-tolyl-propionate) a novel, potent and selective CCK1 receptor antagonist. In vitro and in vivo pharmacological comparison with dexloxiglumide. J Pharmacol Exp Ther 323: 562-569.
    • (2007) J Pharmacol Exp Ther , vol.323 , pp. 562-569
    • Morton, M.F.1    Barrett, T.D.2    Yan, W.3    Freedman, J.M.4    Lagaud, G.5    Prendergast, C.E.6
  • 9
    • 0022098518 scopus 로고
    • Effects of proglumide on ductal and basolateral secretion of pancreatic digestive enzymes
    • Niederau C, Grendell JH, Rothman SS (1985). Effects of proglumide on ductal and basolateral secretion of pancreatic digestive enzymes. Am J Physiol 249: G100-G107.
    • (1985) Am J Physiol , vol.249
    • Niederau, C.1    Grendell, J.H.2    Rothman, S.S.3
  • 10
    • 0023025329 scopus 로고
    • Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis
    • Niederau C, Liddle RA, Ferrell LD, Grendell JH (1986). Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. J Clin Invest 78: 1056-1063.
    • (1986) J Clin Invest , vol.78 , pp. 1056-1063
    • Niederau, C.1    Liddle, R.A.2    Ferrell, L.D.3    Grendell, J.H.4
  • 11
    • 0033055734 scopus 로고    scopus 로고
    • Clinical evaluation of cholecystokinin-A-receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan
    • Ochi K, Harada H, Satake K (1999). Clinical evaluation of cholecystokinin-A-receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan. Digestion 60 (Suppl 1): 81-85.
    • (1999) Digestion , vol.60 , Issue.SUPPL. 1 , pp. 81-85
    • Ochi, K.1    Harada, H.2    Satake, K.3
  • 12
    • 0033900819 scopus 로고    scopus 로고
    • Acute taurodeoxycholate-induced pancreatitis in the rat is associated with hyperCCKemia
    • Ohlsson B, Axelson J, Stenram U, Rehfeld JF, Ihse I (2000). Acute taurodeoxycholate-induced pancreatitis in the rat is associated with hyperCCKemia. Int J Pancreatol 27: 195-201.
    • (2000) Int J Pancreatol , vol.27 , pp. 195-201
    • Ohlsson, B.1    Axelson, J.2    Stenram, U.3    Rehfeld, J.F.4    Ihse, I.5
  • 13
    • 0034075546 scopus 로고    scopus 로고
    • Pathophysiological role of cholecystokinin in humans
    • Otsuki M (2000). Pathophysiological role of cholecystokinin in humans. J Gastroenterol Hepatol 15: D71-D83.
    • (2000) J Gastroenterol Hepatol , vol.15
    • Otsuki, M.1
  • 14
    • 4444354589 scopus 로고    scopus 로고
    • New insights into neurohormonal regulation of pancreatic secretion
    • Owyang C, Logsdon CD (2004). New insights into neurohormonal regulation of pancreatic secretion. Gastroenterology 127: 957-969.
    • (2004) Gastroenterology , vol.127 , pp. 957-969
    • Owyang, C.1    Logsdon, C.D.2
  • 15
    • 0036251597 scopus 로고    scopus 로고
    • Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males
    • Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC (2002). Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int J Clin Pharmacol Ther 40: 198-206.
    • (2002) Int J Clin Pharmacol Ther , vol.40 , pp. 198-206
    • Persiani, S.1    D'Amato, M.2    Makovec, F.3    Tavares, I.A.4    Bishai, P.M.5    Rovati, L.C.6
  • 16
    • 0033056955 scopus 로고    scopus 로고
    • Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models
    • Satake K, Kimura K, Saito T (1999). Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models. Digestion 60 (Suppl 1): 64-68.
    • (1999) Digestion , vol.60 , Issue.SUPPL. 1 , pp. 64-68
    • Satake, K.1    Kimura, K.2    Saito, T.3
  • 18
    • 18744389156 scopus 로고    scopus 로고
    • Shiratori K, Takeuchi T, Satake K, Matsuno S, Study Group of Loxiglumide in Japan (2002). Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. Pancreas 25: e1-e5.
    • Shiratori K, Takeuchi T, Satake K, Matsuno S, Study Group of Loxiglumide in Japan (2002). Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. Pancreas 25: e1-e5.
  • 19
    • 0030937508 scopus 로고    scopus 로고
    • Plasma cholecystokinin levels in acute pancreatitis
    • Shirohara H, Otsuki M (1997). Plasma cholecystokinin levels in acute pancreatitis. Pancreas 14: 249-254.
    • (1997) Pancreas , vol.14 , pp. 249-254
    • Shirohara, H.1    Otsuki, M.2
  • 21
    • 3142752464 scopus 로고    scopus 로고
    • Disorders of the pancreas
    • Braunwald E, Fauci AS, Kasper DL et al, eds, McGraw-Hill: New York, NY. pp
    • Toskes PP, Greenberger NJ (2001). Disorders of the pancreas. In: Braunwald E, Fauci AS, Kasper DL et al. (eds). Harrison's 15th Edition. Principles of Internal Medicine. McGraw-Hill: New York, NY. pp 1788-1804.
    • (2001) Harrison's 15th Edition. Principles of Internal Medicine , pp. 1788-1804
    • Toskes, P.P.1    Greenberger, N.J.2
  • 22
    • 0028845124 scopus 로고
    • Cholecystokinin receptors
    • Wank SA (1995). Cholecystokinin receptors. Am J Physiol 269: G628-G646.
    • (1995) Am J Physiol , vol.269
    • Wank, S.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.